Arbitel – is shown for treatment of essential hypertensia at adults.

Prevention of cardiovascular diseases.

Decrease in incidence of cardiovascular diseases at patients with:

• significant manifestations of an aterotrombotichesky cardiovascular disease (coronary heart disease, a stroke or a disease of peripheral arteries in the anamnesis);
• diabetes ІІ type with the diagnosed damage of target organs.

Structure

• active ingredient: telmisartan;
• 1 tablet contains 40 mg of a telmisartan;
• other components: mannitol (E 421), Megluminum, sodium hydroxide, povidone (K-30), krospovidon (type A), magnesium stearate.

Contraindication

• hypersensitivity to medicament components;
• pregnancy or planning;
• obstructive biliary disturbances;
• heavy disturbances of functions of a liver;
• children's age (up to 18 years);
• simultaneous use of a telmisartan and aliskirensoderzhashchy products to patients with diabetes or renal failures (SKF <60 ml/min. / 1.73 sq.m).

Serious by-effects including anaphylactic reaction and a Quincke's disease are possible

in rare instances (from ≥ 1/10000 to <1/1000) and also OPN was observed.

Route of administration

Treatment of arterial hypertension.

Usual effective dose of a telmisartan makes 40 mg/days. Some patients can have a sufficient daily dose of a telmisartan in 20 mg. In case arterial blood pressure does not decrease to desirable value, the dose of a telmisartan can be raised to 80 mg of 1 times a day. Alternatively telmisartan it is possible to appoint in a combination with thiazide diuretics, such as hydrochlorothiazide having additional effect on decrease in the ABP at use with telmisartany. At the solution of an issue of increase in a dose it must be kept in mind that the maximum hypotensive effect is reached in 4-8 weeks from an initiation of treatment.

Prevention of cardiovascular diseases.

Recommended dose makes 80 mg once a day. The efficiency of a telmisartan in doses less than 80 mg at prevention of cardiovascular diseases is unknown.

Starting treatment telmisartany for the purpose of decrease in cardiovascular diseases, it is recommended to carry out careful control of arterial blood pressure and in case of need to adjust a dose of the medicaments reducing arterial blood pressure.

1 time a day orally with enough liquid irrespective of food.

Tablet should be stored in the soldered blister for protection against moisture. Tablets need to be taken from the blister just before use.

Use during pregnancy or feeding by a breast

Medicine it is contraindicated to the pregnant women or women who are going to become pregnant to apply

Feature of use

Due to the lack of information on use of a telmisartan during feeding by a breast of ARBITEL it is not recommended for use to the women nursing. Preference is given to alternative treatment with better the studied safety profile, especially when feeding by a breast of the newborn or premature child. Feeding period breast.

Children

did not investigate Safety and efficiency of a telmisartan at children (up to 18 years).

Ability to influence speed of response at control of motor transport or other mechanisms

When driving and other mechanical devices needs to consider possibility of dizziness or a hypersomnia at antihypertensive therapy, including medicament ARBITEL.

Information on overdose telmisartany is limited to

.

Symptoms. Hypotension and tachycardia were the most expressed symptoms of overdose of a telmisartan. Also reported about bradycardia, dizziness, increase in concentration of creatinine in blood serum and OPN.

Therapy. Telmisartan it is not brought out of an organism by a hemodialysis. Patients have to be under control and receive symptomatic and maintenance therapy. Treatment depends on time which passed after overdose and weight of symptoms. It is recommended to cause vomiting and/or to wash out a stomach. At treatment of overdose it is possible to use activated carbon. It is necessary to check often the level of electrolytes and creatinine in blood serum. When developing arterial hypotension of the patient it is necessary to put on a back and to help, directed to fast replenishment of volume of liquid and salt in an organism.

Interaction with other medicines and other types of interactions

Digoksin

At simultaneous use of a telmisartan and digoxin was noted by

average growth of peak concentration of digoxin in blood plasma (for 49%) and the minimum concentration (for 20%). At the beginning of reception in case of correction of a dose and the termination of reception of a telmisartan it is necessary to conduct monitoring of levels of digoxin for their maintenance within therapeutic range.

Storage conditions

Medicine does not demand special storage conditions.